
|Articles|November 3, 2015
ICON Partners with iCardiac On Phase I
Advertisement
ICON announced that its clinical research unit in San Antonio is a certified and preferred site in iCardiac’s Early Precision QT Program. The certification enables ICON to offer iCardiac’s Early Precision QT® services for evaluating the cardiac safety of new compounds in Phase I clinical trials. More accurate early QT studies may eliminate the need for later stage TQT studies, potentially saving costs.
Read
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor
2
Adaptive Trial Design as a Pathway to Faster Development
3
Setting the Limits of Autonomy with Autonomous Agents for Clinical Research
4
Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer
5